Palliative Care — MCQs

Q: A 70-year-old man with advanced pancreatic cancer on sustained-release morphine 60 mg BD develops breakthrough pain 3-4 times daily. His pain is otherwise well controlled. What should be the dose of immediate-release morphine for breakthrough pain?

12 mg. ***12 mg*** - The standard dose for **breakthrough pain** is calculated as **one-sixth (approx 16%) or 10%** of the **total daily dose** (TDD) of the regular opioid. - Since the patient takes 60 mg twice daily, the **TDD is 120 mg**; 10% of 120 mg is **12 mg**, providing a safe and effective immediate-release dose [1]. *6 mg* - This dose represents only **5%** of the TDD, which is typically insufficient to manage moderate-to-severe **breakthrough pain**. - Using a dose this low may lead to **inadequate analgesia** and multiple repeat doses, which is not clinically optimal [1]. *20 mg* - This dose exceeds the standard **10-16% recommendation** for breakthrough medication in a patient whose pain is otherwise and normally **well controlled**. - High breakthrough doses relative to the TDD increase the risk of **opioid toxicity**, such as excessive sedation or **respiratory depression**. *30 mg* - This is **25%** of the daily dose, which is significantly higher than the recommended safety margin for **palliative care** breakthrough protocols [1]. - Such a high dose would typically only be considered if the **background pain** was also poorly controlled and the oral dose was being titrated upward.

Q: A 58-year-old woman with terminal breast cancer presents with severe nausea and vomiting due to hypercalcemia and gastroparesis. Which antiemetic would be most appropriate?

Haloperidol. ***Haloperidol*** - **Haloperidol** is highly effective for nausea caused by **metabolic derangements** such as **hypercalcemia** because it acts as a potent **D2 receptor antagonist** in the **chemoreceptor trigger zone (CTZ)** [1]. - It is a first-line agent in **palliative care** for chemical causes of vomiting and is generally preferred when multiple systemic factors are at play. *Cyclizine* - This is an **antihistamine** that primarily targets the **vestibular system** and the vomiting center, making it more suitable for **motion sickness** or raised intracranial pressure. - It lacks the specific action on the **CTZ** required to effectively manage nausea secondary to **hypercalcemia** [1]. *Ondansetron* - This **5-HT3 receptor antagonist** is primarily indicated for **chemotherapy-induced** or postoperative nausea and vomiting. - It is frequently associated with **constipation**, which can worsen the gastrointestinal distress already present in patients with **hypercalcemia** and gastroparesis. *Metoclopramide* - While it has **prokinetic** properties, its efficacy is limited in the context of **hypercalcemia-induced** nausea which is mediated chemically via the brain rather than just mechanically. - Although useful for mild **gastroparesis**, it is less effective than central dopamine antagonists for the systemic metabolic triggers seen in terminal malignancy cases.

Q: A 65-year-old man with metastatic lung cancer is receiving oral morphine 30 mg every 4 hours for pain control. He develops severe dysphagia and cannot take oral medications. What is the appropriate 24-hour subcutaneous morphine dose?

90 mg. ***90 mg*** - The patient's total daily dose of **oral morphine** is 180 mg (30 mg every 4 hours, which is 6 doses per day) [1]. - When converting from **oral to subcutaneous morphine**, a **conversion ratio of 2:1** is used due to the higher bioavailability of parenteral administration; thus, 180 mg oral / 2 = 90 mg subcutaneous [1]. *60 mg* - This dose would represent a **3:1 conversion ratio**, which is more commonly used for converting oral morphine to **intravenous/subcutaneous diamorphine** in some guidelines, not morphine to morphine. - Using this dose would result in **undermedication** and inadequate pain control for this patient with metastatic cancer. *180 mg* - This is a **1:1 conversion ratio**, which ignores the **first-pass metabolism** that oral morphine undergoes. - Administering the same dose subcutaneously would likely lead to **opioid toxicity**, characterized by respiratory depression and sedation, because parenteral morphine is much more potent [1]. *45 mg* - This dose represents a **4:1 conversion ratio**, which is significantly lower than the standard clinical recommendation for **opioid rotation** from oral to SC morphine [1]. - Such a low dose would likely cause a **pain crisis** or withdrawal symptoms due to insufficient analgesia for the patient's existing needs.

Q: Why is dexamethasone preferred over other corticosteroids for symptom management in terminal cancer patients?

It has the least mineralocorticoid activity. ***It has the least mineralocorticoid activity*** - **Dexamethasone** possesses negligible **mineralocorticoid activity**, which significantly reduces the risk of **fluid retention**, edema, and hypertension in fragile terminal patients. - Its high **glucocorticoid potency** and long **biological half-life** make it highly effective for managing **cerebral edema**, nausea, and cancer-related pain with once-daily dosing [1]. *It has maximum immunosuppressive effect* - While it is a potent immunosuppressant, this is generally a **side effect** or a secondary goal rather than the primary reason for its preference in **symptom palliation**. - Prednisone or other steroids could provide significant immunosuppression, but they carry a higher risk of **fluid-related complications**. *It has shorter half-life allowing better control* - This is incorrect; Dexamethasone has a **long half-life** (36-72 hours), which is preferred because it allows for **infrequent dosing** and maintains stable plasma levels. - **Hydrocortisone** has a shorter half-life but requires multiple doses daily, which increases the **treatment burden** for palliative patients. *It does not cross blood-brain barrier* - Dexamethasone **readily crosses** the **blood-brain barrier**, which is exactly why it is the drug of choice for treating **peritumoral brain edema**. - Its ability to penetrate the **central nervous system** helps alleviate symptoms like headaches and neurological deficits caused by **brain metastases**.

Q: According to WHO analgesic ladder for cancer pain management, which medication should be added at Step 2?

Weak opioids. ***Weak opioids*** - Step 2 of the **WHO analgesic ladder** is indicated for **mild to moderate pain** and involves the addition of **weak opioids** such as **codeine** or **tramadol** to non-opioid medications [1]. - These are often administered in combination with **paracetamol** or **NSAIDs** to enhance analgesic efficacy through different mechanisms of action [1]. *Ketamine* - **Ketamine** is an **NMDA receptor antagonist** used as an **adjuvant** for complex or refractory pain, but it is not a standard component of the three basic steps. - It is typically reserved for specialized pain management rather than being a routine step 2 medication. *Strong opioids* - **Strong opioids**, such as **morphine**, **fentanyl**, or **oxycodone**, are the hallmark of **Step 3** of the ladder [1]. - Step 3 is reserved for **moderate to severe pain** or when pain is not controlled by weak opioids [1]. *NSAIDs alone* - Using **NSAIDs alone** constitutes **Step 1** of the WHO ladder, which is intended for **mild pain** [1]. - In Step 2, non-opioids like NSAIDs are continued as **background therapy**, but the defining addition is the opioid component.

Q: Which of the following is the most appropriate opioid for initiation of pain management in a patient with moderate to severe cancer pain who is opioid-naive?

Morphine immediate release. ***Morphine immediate release*** - **Morphine immediate release (IR)** is the gold standard for initiating opioid therapy in **opioid-naive** patients because it allows for rapid **dose titration** to achieve effective analgesia. [1] - It has a predictable **pharmacokinetic profile**, making it safer and easier to adjust based on the patient's individual pain requirements and response. [1] *Fentanyl transdermal patch* - **Fentanyl patches** are contraindicated in **opioid-naive** patients due to the high risk of **respiratory depression** from a slow-onset, potent dose. [1] - These patches have a long **half-life** and take 12-24 hours to reach steady-state, making them unsuitable for acute dose escalation. [1] *Buprenorphine sublingual* - **Buprenorphine** is a **partial mu-opioid agonist** and has a "ceiling effect" for analgesia, which may limit its utility in severe escalating cancer pain. - While useful in certain settings, it is generally not the first choice for **initial titration** when compared to pure agonists like morphine. *Methadone* - **Methadone** has a very long and **unpredictable half-life**, which increases the danger of accumulation and **toxicity** in patients not already accustomed to opioids. [1] - It requires sophisticated titration due to its complex **pharmacokinetics** and potential to cause **QT interval prolongation**.

Palliative Care Indian Medical PG Practice Questions and MCQs

Question 1: A 68-year-old man with terminal lung cancer develops confusion, myoclonus, and hallucinations after being on high-dose morphine (240 mg/day oral) for 2 weeks. His renal function shows creatinine 2.8 mg/dL. What is the most appropriate management considering the pathophysiology?

A. Continue morphine but add naloxone infusion
B. Add haloperidol for delirium and continue morphine
C. Switch to fentanyl as it has no active metabolites and dose adjust for renal function (Correct Answer)
D. Stop all opioids and use only adjuvant analgesics

Explanation: ***Switch to fentanyl as it has no active metabolites and dose adjust for renal function*** - The patient is experiencing **opioid-induced neurotoxicity (OIN)** due to the accumulation of morphine metabolites, specifically **Morphine-3-glucuronide (M3G)** and **Morphine-6-glucuronide (M6G)**, which are cleared renally. - **Fentanyl** is the preferred opioid in renal impairment because it has no clinically significant active metabolites and does not undergo significant renal excretion [1]. *Continue morphine but add naloxone infusion* - Adding **naloxone** would reverse the analgesic effects and likely precipitate an acute **withdrawal syndrome** or uncontrolled cancer pain. - This does not address the underlying cause, which is the accumulation of **neuroexcitatory metabolites** in the setting of renal failure. *Add haloperidol for delirium and continue morphine* - **Haloperidol** may mask the symptoms of delirium but does not stop the progression of **myoclonus** or neurotoxicity caused by toxic metabolites. - Continuing morphine in a patient with a **creatinine of 2.8 mg/dL** will lead to further metabolite accumulation and potential seizures. *Stop all opioids and use only adjuvant analgesics* - Abruptly stopping opioids in a patient on a high dose (240 mg/day) will lead to severe **withdrawal** and a massive **pain crisis**. - Terminal lung cancer pain requires effective opioid management; switching to a safer agent (opioid rotation) is the standard of care rather than complete discontinuation [1].

Question 2: A 62-year-old woman with advanced ovarian cancer has been on oral morphine 90 mg BD for 3 months. She now reports reduced pain relief despite increasing doses, but experiences severe pain at specific sites of bone metastases. What is the best management strategy?

A. Add ketamine infusion for opioid resistance
B. Switch to fentanyl patch and continue dose escalation
C. Add gabapentin and consider palliative radiotherapy to metastatic sites (Correct Answer)
D. Rotate to hydromorphone at equianalgesic dose

Explanation: ***Add gabapentin and consider palliative radiotherapy to metastatic sites*** - Bone metastases often cause **neuropathic pain** and inflammatory response; adding a **gabapentinoid** treats the nerve-related component that opioids may not fully cover [1]. - **Palliative radiotherapy** is highly effective for localized bone pain, often allowing for **reduced opioid requirements** and improved quality of life. *Add ketamine infusion for opioid resistance* - While **ketamine** is an NMDA antagonist used for refractory pain, it is generally reserved for specialists when common adjuncts and localized treatments fail. - It is a more invasive and complex intervention compared to **radiotherapy** and oral adjuvants like **gabapentin** for focal bone pain. *Switch to fentanyl patch and continue dose escalation* - Increasing the dose of a different opioid (dose escalation) is unlikely to resolve **opioid-insensitive** bone pain and may increase the risk of **opioid-induced hyperalgesia** [2]. - Transdermal **fentanyl** is more suitable for stable pain control and does not address the localized, metastatic nature of the patient's pain [1]. *Rotate to hydromorphone at equianalgesic dose* - **Opioid rotation** to hydromorphone is helpful if the patient is experiencing side effects, but it does not address the underlying pathology of **bone metastases** [1]. - Rotation alone does not provide the specific **neuropathic** or **anti-tumor** benefits offered by the combination of gabapentin and radiotherapy.

Question 3: A 55-year-old man with terminal esophageal cancer develops respiratory secretions causing death rattle. Despite positioning and suctioning, the symptom persists. Which medication would be most appropriate and why?

A. Morphine - reduces respiratory drive and secretions
B. Hyoscine butylbromide - antimuscarinic action reduces secretions without sedation (Correct Answer)
C. Midazolam - sedates patient reducing awareness of secretions
D. Furosemide - reduces fluid overload causing secretions

Explanation: Hyoscine butylbromide - antimuscarinic action reduces secretions without sedation - **Hyoscine butylbromide** is the preferred medication for the **death rattle** because its **antimuscarinic properties** effectively dry up salivary and bronchial secretions. - Unlike hyoscine hydrobromide, it does not cross the **blood-brain barrier**, meaning it reduces secretions with minimal risk of **sedation** or **delirium**. *Morphine - reduces respiratory drive and secretions* - While **morphine** is excellent for managing **dyspnea** and pain at the end of life, it does not possess **antisecretory** properties to manage a death rattle [1]. - Overuse of opioids for secretions can lead to unnecessary **respiratory depression** or decreased level of consciousness without fixing the noisy breathing. *Midazolam - sedates patient reducing awareness of secretions* - **Midazolam** is a benzodiazepine used for **terminal agitation** or anxiety but does not affect the production of **respiratory secretions**. - Although it might reduce patient awareness, it does not address the **audible noise** which is often distressing for the family members observing the patient [2]. *Furosemide - reduces fluid overload causing secretions* - **Furosemide** is indicated for **pulmonary edema** caused by congestive heart failure, not for the terminal accumulation of oropharyngeal secretions. - Using diuretics in a terminal patient with a death rattle is generally **ineffective** as the noise is caused by pooled saliva rather than **systemic fluid overload**.

Question 4: A 70-year-old man with advanced pancreatic cancer on sustained-release morphine 60 mg BD develops breakthrough pain 3-4 times daily. His pain is otherwise well controlled. What should be the dose of immediate-release morphine for breakthrough pain?

A. 6 mg
B. 12 mg (Correct Answer)
C. 20 mg
D. 30 mg

Explanation: ***12 mg*** - The standard dose for **breakthrough pain** is calculated as **one-sixth (approx 16%) or 10%** of the **total daily dose** (TDD) of the regular opioid. - Since the patient takes 60 mg twice daily, the **TDD is 120 mg**; 10% of 120 mg is **12 mg**, providing a safe and effective immediate-release dose [1]. *6 mg* - This dose represents only **5%** of the TDD, which is typically insufficient to manage moderate-to-severe **breakthrough pain**. - Using a dose this low may lead to **inadequate analgesia** and multiple repeat doses, which is not clinically optimal [1]. *20 mg* - This dose exceeds the standard **10-16% recommendation** for breakthrough medication in a patient whose pain is otherwise and normally **well controlled**. - High breakthrough doses relative to the TDD increase the risk of **opioid toxicity**, such as excessive sedation or **respiratory depression**. *30 mg* - This is **25%** of the daily dose, which is significantly higher than the recommended safety margin for **palliative care** breakthrough protocols [1]. - Such a high dose would typically only be considered if the **background pain** was also poorly controlled and the oral dose was being titrated upward.

Question 5: A 58-year-old woman with terminal breast cancer presents with severe nausea and vomiting due to hypercalcemia and gastroparesis. Which antiemetic would be most appropriate?

A. Cyclizine
B. Ondansetron
C. Haloperidol (Correct Answer)
D. Metoclopramide

Explanation: ***Haloperidol*** - **Haloperidol** is highly effective for nausea caused by **metabolic derangements** such as **hypercalcemia** because it acts as a potent **D2 receptor antagonist** in the **chemoreceptor trigger zone (CTZ)** [1]. - It is a first-line agent in **palliative care** for chemical causes of vomiting and is generally preferred when multiple systemic factors are at play. *Cyclizine* - This is an **antihistamine** that primarily targets the **vestibular system** and the vomiting center, making it more suitable for **motion sickness** or raised intracranial pressure. - It lacks the specific action on the **CTZ** required to effectively manage nausea secondary to **hypercalcemia** [1]. *Ondansetron* - This **5-HT3 receptor antagonist** is primarily indicated for **chemotherapy-induced** or postoperative nausea and vomiting. - It is frequently associated with **constipation**, which can worsen the gastrointestinal distress already present in patients with **hypercalcemia** and gastroparesis. *Metoclopramide* - While it has **prokinetic** properties, its efficacy is limited in the context of **hypercalcemia-induced** nausea which is mediated chemically via the brain rather than just mechanically. - Although useful for mild **gastroparesis**, it is less effective than central dopamine antagonists for the systemic metabolic triggers seen in terminal malignancy cases.

Question 6: A 65-year-old man with metastatic lung cancer is receiving oral morphine 30 mg every 4 hours for pain control. He develops severe dysphagia and cannot take oral medications. What is the appropriate 24-hour subcutaneous morphine dose?

A. 90 mg (Correct Answer)
B. 60 mg
C. 180 mg
D. 45 mg

Explanation: ***90 mg*** - The patient's total daily dose of **oral morphine** is 180 mg (30 mg every 4 hours, which is 6 doses per day) [1]. - When converting from **oral to subcutaneous morphine**, a **conversion ratio of 2:1** is used due to the higher bioavailability of parenteral administration; thus, 180 mg oral / 2 = 90 mg subcutaneous [1]. *60 mg* - This dose would represent a **3:1 conversion ratio**, which is more commonly used for converting oral morphine to **intravenous/subcutaneous diamorphine** in some guidelines, not morphine to morphine. - Using this dose would result in **undermedication** and inadequate pain control for this patient with metastatic cancer. *180 mg* - This is a **1:1 conversion ratio**, which ignores the **first-pass metabolism** that oral morphine undergoes. - Administering the same dose subcutaneously would likely lead to **opioid toxicity**, characterized by respiratory depression and sedation, because parenteral morphine is much more potent [1]. *45 mg* - This dose represents a **4:1 conversion ratio**, which is significantly lower than the standard clinical recommendation for **opioid rotation** from oral to SC morphine [1]. - Such a low dose would likely cause a **pain crisis** or withdrawal symptoms due to insufficient analgesia for the patient's existing needs.

Question 7: Why is dexamethasone preferred over other corticosteroids for symptom management in terminal cancer patients?

A. It has the least mineralocorticoid activity (Correct Answer)
B. It has maximum immunosuppressive effect
C. It has shorter half-life allowing better control
D. It does not cross blood-brain barrier

Explanation: ***It has the least mineralocorticoid activity*** - **Dexamethasone** possesses negligible **mineralocorticoid activity**, which significantly reduces the risk of **fluid retention**, edema, and hypertension in fragile terminal patients. - Its high **glucocorticoid potency** and long **biological half-life** make it highly effective for managing **cerebral edema**, nausea, and cancer-related pain with once-daily dosing [1]. *It has maximum immunosuppressive effect* - While it is a potent immunosuppressant, this is generally a **side effect** or a secondary goal rather than the primary reason for its preference in **symptom palliation**. - Prednisone or other steroids could provide significant immunosuppression, but they carry a higher risk of **fluid-related complications**. *It has shorter half-life allowing better control* - This is incorrect; Dexamethasone has a **long half-life** (36-72 hours), which is preferred because it allows for **infrequent dosing** and maintains stable plasma levels. - **Hydrocortisone** has a shorter half-life but requires multiple doses daily, which increases the **treatment burden** for palliative patients. *It does not cross blood-brain barrier* - Dexamethasone **readily crosses** the **blood-brain barrier**, which is exactly why it is the drug of choice for treating **peritumoral brain edema**. - Its ability to penetrate the **central nervous system** helps alleviate symptoms like headaches and neurological deficits caused by **brain metastases**.

Question 8: What is the mechanism by which opioids cause constipation in palliative care patients?

A. Inhibition of bile secretion
B. Direct toxic effect on intestinal mucosa
C. Activation of mu receptors in myenteric plexus reducing peristalsis (Correct Answer)
D. Dehydration due to increased renal sodium excretion

Explanation: ***Activation of mu receptors in myenteric plexus reducing peristalsis*** - Opioids bind to **mu-opioid receptors** in the enteric nervous system, specifically the **myenteric plexus**, leading to a significant decrease in **propulsive peristaltic contractions**. [1] - This activation also increases **sphincter tone** and promotes excessive **fluid absorption**, resulting in the hard, dry stools characteristic of **opioid-induced constipation (OIC)**. [1] *Inhibition of bile secretion* - Bile secretion is not the primary target of opioid action in the gut; OIC is driven by **motility** and **secretory** changes rather than malabsorption of fats. - While opioids can cause **sphincter of Oddi dysfunction**, this leads to biliary pain rather than the systemic constipation seen in palliative care. *Direct toxic effect on intestinal mucosa* - Opioids do not cause **structural damage** or toxicity to the **intestinal epithelial lining**; their effects are purely functional and mediated by receptors. - Unlike certain chemotherapeutic agents that cause **mucositis**, opioids leave the mucosa intact while slowing the **transit time**. *Dehydration due to increased renal sodium excretion* - Opioids do not have a primary mechanism of increasing **renal sodium excretion** or causing systemic dehydration via the kidneys. - Although dehydration can worsen constipation, the primary cause in these patients is the local effect of the drug on **intestinal transit** and increased **colonic water reabsorption**.

Question 9: According to WHO analgesic ladder for cancer pain management, which medication should be added at Step 2?

A. Ketamine
B. Strong opioids
C. Weak opioids (Correct Answer)
D. NSAIDs alone

Explanation: ***Weak opioids*** - Step 2 of the **WHO analgesic ladder** is indicated for **mild to moderate pain** and involves the addition of **weak opioids** such as **codeine** or **tramadol** to non-opioid medications [1]. - These are often administered in combination with **paracetamol** or **NSAIDs** to enhance analgesic efficacy through different mechanisms of action [1]. *Ketamine* - **Ketamine** is an **NMDA receptor antagonist** used as an **adjuvant** for complex or refractory pain, but it is not a standard component of the three basic steps. - It is typically reserved for specialized pain management rather than being a routine step 2 medication. *Strong opioids* - **Strong opioids**, such as **morphine**, **fentanyl**, or **oxycodone**, are the hallmark of **Step 3** of the ladder [1]. - Step 3 is reserved for **moderate to severe pain** or when pain is not controlled by weak opioids [1]. *NSAIDs alone* - Using **NSAIDs alone** constitutes **Step 1** of the WHO ladder, which is intended for **mild pain** [1]. - In Step 2, non-opioids like NSAIDs are continued as **background therapy**, but the defining addition is the opioid component.

Question 10: Which of the following is the most appropriate opioid for initiation of pain management in a patient with moderate to severe cancer pain who is opioid-naive?

A. Fentanyl transdermal patch
B. Morphine immediate release (Correct Answer)
C. Buprenorphine sublingual
D. Methadone

Explanation: ***Morphine immediate release*** - **Morphine immediate release (IR)** is the gold standard for initiating opioid therapy in **opioid-naive** patients because it allows for rapid **dose titration** to achieve effective analgesia. [1] - It has a predictable **pharmacokinetic profile**, making it safer and easier to adjust based on the patient's individual pain requirements and response. [1] *Fentanyl transdermal patch* - **Fentanyl patches** are contraindicated in **opioid-naive** patients due to the high risk of **respiratory depression** from a slow-onset, potent dose. [1] - These patches have a long **half-life** and take 12-24 hours to reach steady-state, making them unsuitable for acute dose escalation. [1] *Buprenorphine sublingual* - **Buprenorphine** is a **partial mu-opioid agonist** and has a "ceiling effect" for analgesia, which may limit its utility in severe escalating cancer pain. - While useful in certain settings, it is generally not the first choice for **initial titration** when compared to pure agonists like morphine. *Methadone* - **Methadone** has a very long and **unpredictable half-life**, which increases the danger of accumulation and **toxicity** in patients not already accustomed to opioids. [1] - It requires sophisticated titration due to its complex **pharmacokinetics** and potential to cause **QT interval prolongation**.

Practice by Chapter

Pain Assessment and Management

Practice Questions

Symptom Control in Advanced Illness

Practice Questions

Communication in Serious Illness

Practice Questions

Advance Care Planning

Practice Questions

Ethical Issues in End-of-Life Care

Practice Questions

Psychosocial Aspects of Palliative Care

Practice Questions

Spiritual Care

Practice Questions

Palliative Care in Non-Cancer Conditions

Practice Questions

Hospice Care

Practice Questions

Family Support and Bereavement

Practice Questions

Palliative Sedation

Practice Questions

Interdisciplinary Team Approach

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free